.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers have recently achieved a significant milestone in radical-based photodynamic therapy by developing water-soluble, self-assembled nanoparticles. Traditional organic luminescent radicals often struggle with water insolubility. However, this new amphiphilic organic radical, TTM-2PyPh, successfully forms nanoparticles (TTM-2PyPhSA@NPs) that maintain deep-red emission.
These nanoparticles act as efficient Type I and Type II photosensitizers. Specifically, the doublet emission of the radicals allows them to transfer energy and electrons directly to oxygen. Quantum chemistry calculations confirm this efficient transfer process. Consequently, the particles can produce reactive oxygen species more effectively than older agents like chlorin e6 and methylene blue.
In vivo studies show that these nanoparticles target tumors with high precision through self-assembly. Moreover, they provide deep-red fluorescence, which guides the therapy in real-time. This dual-functionality ensures that doctors can visualize the treatment area while simultaneously eradicating malignant cells. The nanoparticles demonstrated superior tumor eradication in animal models compared to traditional core-shell structures. Furthermore, the stability and solubility of these radical-based systems make them promising candidates for clinical translation.
Ultimately, this innovation addresses the long-standing challenge of delivering hydrophobic photosensitizers into the bloodstream. Therefore, it opens new avenues for enhancing the efficacy of photodynamic treatments in oncology. Scientists believe this approach will pave the way for a new generation of water-soluble radical-based photosensitizers.
Unlike traditional photosensitizers, these nanoparticles use organic luminescent radicals that are water-soluble and provide deep-red fluorescence. This allows for both better delivery in the body and more precise imaging during treatment.
Type I therapy involves electron transfer to create free radicals, while Type II therapy involves energy transfer to create singlet oxygen. These new nanoparticles are unique because they efficiently perform both processes.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.
References
Li Z et al. Water-Soluble Self-Assembled Radical Nanoparticles for Deep-Red Fluorescence-Guided Type I/II Photodynamic Therapy. Small. 2026 May 03. doi: 10.1002/smll.202514934. PMID: 42070288.
Wang J, et al. Recent advances in radical-based photosensitizers. Mater Chem Front. 2023;7(2):124-145.
Hamblin MR. Photodynamic therapy for cancer: what's past is prologue. Photochem Photobiol. 2020;96(3):506-516.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
New research introduces TTM-2PyPhSA@NPs, a water-soluble radical-based photosensitizer that outperforms traditional PDT agents in tumor eradication....
5 months ago
A retrospective cohort study of 7,716 ICU patients from the MIMIC-IV database demonstrates that Gradient Boosting Decision Trees significantly outperform traditional SOFA scores in predicting in-hospital mortality among patients with sepsis and diabetes, with SHAP analysis providing clinical interpretability.
Today
Occult maternal malignancy accounts for 3.82% of persistent unreportable NIPT results with genomic noise. Multiple chromosomal aberrations, notably on chromosome 18, warrant thorough oncological evaluation and whole-body MRI to ensure timely maternal diagnosis while preserving fetal care.
Today
This article reviews the forensic and clinical complexities of acute myocarditis arising on left ventricular hypertrophy in children, highlighting early diagnostic red flags and multidisciplinary postmortem autopsy protocols.
Today
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday
